Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma

被引:2
|
作者
Yu, Ming-Chin [1 ,2 ,7 ]
Wu, Tsung-Han [1 ,7 ]
Lee, Chao-Wei [1 ,7 ]
Lee, Yun-Shien [3 ,4 ]
Lian, Jang-Hau [3 ]
Tsai, Chia-Lung [3 ]
Hsieh, Sen-Yung [5 ,7 ]
Tsai, Chi-Neu [1 ,6 ,7 ]
机构
[1] Chang Gung Mem Hosp Linkou, Dept Surg, Taoyuan, Taiwan
[2] New Taipei Municipal TuCheng Hosp, Dept Surg, New Taipei, Taiwan
[3] Chang Gung Mem Hosp Linkou, Genom Med Res Core Lab, Taoyuan, Taiwan
[4] Ming Chuan Univ, Dept Biotechnol, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp Linkou, Dept Gastroenterol & Hepatol Linkou, Taoyuan, Taiwan
[6] Chang Gung Univ, Grad Inst Clin Med Sci, 259 Wenhu 1st Rd, Taoyuan 333, Taiwan
[7] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
关键词
Advanced HCC; Sorafenib; Copy number aberrations; 7q amplification; ABCB1; COPY NUMBER; P-GLYCOPROTEIN; CANCER-CELLS; RISK-FACTORS; RESISTANCE; RECURRENCE; MECHANISM; RESECTION; ACTIVATION; EXPRESSION;
D O I
10.1016/j.bj.2020.07.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Hepatocellular carcinoma (HCC) may arise from genomic instability and has dismal outcome. Sorafenib is the first-line treatment for advanced stage HCC, but its therapeutic efficacy is less than 50%. Biomarkers for predicting the therapeutic efficacy of sorafenib administration to patients with advanced HCC are required. Here, we evaluated the role of chromosomal copy number aberrations (CNAs) in patients with advanced HCC who were treated with sorafenib along with their drug response. Methods: The response to sorafenib treatment of twenty-three HCC patients who developed advanced recurrence after partial hepatectomy was analyzed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Formalin fixed paraffin embedded (FFPE) tissue specimens obtained after tumor resection were analyzed using the Affymetrix OncoScan (R) FFPE assay. Results: From the 23 patients analyzed in this study, 7 (30.4%) had complete/partial response to sorafenib (CR/PR), 7 (30.4%) had stable disease (SD), and 9 (39.1%) had progressive disease (PD). The mean genome-wide percentage of genome change acquisition via the OncoScan platform was 19.8% for patients with CR/PR/SD and 50.02% in the PD group (p = 0.055). Percentage of genome change above 33% was associated with adverse outcomes for sorafenib treatment in the time-to-progression analysis (p = 0.007) and overall survival (p = 0.096). Among these CNAs, amplification of chromosome 7q, containing the multidrug resistance gene ATP Binding Cassette Subfamily B Member 1 (ACBC1), significantly associated with poor overall survival (p = 0.004) and time-to-progression (p < 0.001). Conclusions: Higher percentage genome change and amplification of chromosome 7q in advanced HCC is associated with sorafenib resistance.
引用
收藏
页码:S73 / S83
页数:11
相关论文
共 50 条
  • [1] DNA amplification on chromosome 7q in squamous cell carcinoma of the tongue
    Steinhart, H
    Bohlender, J
    Iro, H
    Jung, V
    Constantinidis, J
    Gebhart, E
    Pahl, S
    Urbschat, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (04) : 851 - 855
  • [2] Chromosome 7q allelic losses in pancreatic carcinoma
    Achille, A
    Biasi, MO
    Zamboni, G
    Bogina, G
    Magalini, AR
    Pederzoli, P
    Perucho, M
    Scarpa, A
    CANCER RESEARCH, 1996, 56 (16) : 3808 - 3813
  • [3] Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
    Huang, Song-Fong
    Chong, Sio-Wai
    Huang, Chun-Wei
    Hsu, Heng-Yuan
    Pan, Kuang-Tse
    Hung, Chien-Fu
    Wu, Tsung-Han
    Lee, Chao-Wei
    Hsieh, Chia-Hsun
    Wang, Ching-Ting
    Chai, Pei-Mei
    Yu, Ming-Chin
    BIOMEDICINES, 2022, 10 (09)
  • [4] Interrogating chromosome 8q amplification in hepatocellular carcinoma
    Reghupaty, S.
    Mendoza, R.
    Dozmorov, M.
    Fisher, P.
    Ebeid, K.
    Salem, A.
    Sarkar, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 38 - 38
  • [5] A full genome screen for autism with evidence for linkage to a region on chromosome 7q
    Bailey, A
    HUMAN MOLECULAR GENETICS, 1998, 7 (03) : 571 - 578
  • [6] The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
    Caputo, Francesco
    Dadduzio, Vincenzo
    Tovoli, Francesco
    Bertolini, Giulia
    Cabibbo, Giuseppe
    Cerma, Krisida
    Vivaldi, Caterina
    Faloppi, Luca
    Rizzato, Mario Domenico
    Piscaglia, Fabio
    Celsa, Ciro
    Fornaro, Lorenzo
    Marisi, Giorgia
    Conti, Fabio
    Silvestris, Nicola
    Silletta, Marianna
    Lonardi, Sara
    Granito, Alessandro
    Stornello, Caterina
    Massa, Valentina
    Astara, Giorgio
    Delcuratolo, Sabina
    Cascinu, Stefano
    Scartozzi, Mario
    Casadei-Gardini, Andrea
    PLOS ONE, 2020, 15 (05):
  • [7] Targeted genome profiling in patients with advanced hepatocellular carcinoma treated with sorafenib
    Kang, Wonseok
    Kim, Kyung
    Lee, Joon Hyeok
    Lim, Ho Yeong
    Park, Woong-Yang
    Lee, Jeeyun
    Paik, Yong Han
    CANCER RESEARCH, 2017, 77
  • [8] Chromosome 8q24 amplification predicts prognosis for patients with advanced hepatocellular carcinoma (HCC).
    Cheng, Yuan
    Huang, Mengli
    Xie, Wenzhuan
    Gao, Chan
    Cai, Shangli
    Ji, Jing
    Pan, Mingxin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] PET-MR can predict survival and response in advanced hepatocellular carcinoma patients treated with sorafenib
    Hwang, Jae-Pil
    Lim, Ilhan
    Han, Chul Ju
    Park, Su Cheol
    Kim, Young Han
    Park, Joon Yeun
    Kim, Kyeong Min
    Kim, Byung Il
    Choi, Chang Woon
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma
    Chen, Leilei
    Chan, Tim Hon Man
    Guan, Xin-yuan
    ACTA PHARMACOLOGICA SINICA, 2010, 31 (09) : 1165 - 1171